

CITATION REPORT

List of articles citing

Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid

DOI: 10.1111/epi.16596
Epilepsia, 2020, 61, e85-e89.

Source: <https://exaly.com/paper-pdf/77206281/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
12	Cannabidiol/valproic-acid. <i>Reactions Weekly</i> , 2020 , 1821, 66-66	0	
11	Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 99-110	4.3	11
10	Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	14
9	Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. <i>CNS Drugs</i> , 2021 , 35, 265-281	6.7	7
8	Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome. <i>Frontiers in Neurology</i> , 2021 , 12, 673135	4.1	5
7	Aggravation of valproic acid induced thrombocytopenia after the introduction of fenfluramine, a case report. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021 , 93, 60-62	3.2	3
6	A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.. <i>CNS Drugs</i> , 2022 , 36, 217	6.7	3
5	Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
4	The Role of Cannabidiol in Neurological Disorders. 2021 , 25,		2
3	Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study.		0
2	Cannabidiol drug interaction considerations for prescribers and pharmacists.		0
1	Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy. 2022 , 137, 108958		0